sisplatin, nivolumab
Nivolumab sisplatin va gemsitabin bilan birgalikda rezektsiya qilinib bo'lmaydigan yoki metastatik urotelial karsinoma uchun USFDA tomonidan tasdiqlangan.
March 2024: The Food and Drug Administration has granted approval for the use of nivolumab (Opdivo, Bristol-Myers Squibb Company) in conjunction with cisplatin and gemcitabine as the initial treatment for adult patients with unres..
Pembrolizumab, USFDA
Pembrolizumab bilan Enfortumab vedotin-ejfv mahalliy darajada rivojlangan yoki metastatik urotelial karsinoma uchun USFDA tomonidan tasdiqlangan.
Feb 2024: The Food and Drug Administration has sped up the approval process for two drugs, enfortumab vedotin-ejfv (Padcev, Astellas Pharma) and pembrolizumab (Keytruda, Merck). These drugs are meant to treat people with locally ..
Bristol Mayers Squibb, CHECKMATE-274, nivolumab, Ajoyib, Uoteliyal karsinoma
Nivolumab FDA tomonidan urotelial karsinoma uchun yordamchi vosita sifatida foydalanish uchun tasdiqlangan.
2021 yil avgust: Nivolumab (Opdivo, Bristol-Myers Squibb Co.) Oziq-ovqat va farmatsevtika idorasi tomonidan urotelial karsinoma (UC) bilan og'rigan bemorlarni yordamchi davolash uchun tasdiqlangan.
Astellas Pharma AQSh, NCT03474107, Sharsharalar, Sinov EV-301
FDA mahalliy rivojlangan yoki metastatik urotelial karsinomani davolash uchun enfortumab vedotin-ejfv ruxsatini berdi.
2021 yil avgust: Enfortumab vedotin-ejfv (Padcev, Astellas Pharma US, Inc.), Nektin-4-ga yo'naltirilgan antikor va mikrotubulalar inhibitörleri kombinatsiyasi oziq-ovqat va farmatsevtika idorasi tomonidan mahalliy kasalliklarga chalingan kattalar bemorlari uchun tasdiqlangan.
Immunomedics Inc., mUC, platina o'z ichiga olgan kimyoterapiya, dasturlashtirilgan o'lim retseptorlari-1, sacituzumab govitekan, Trodelvy, o'lja
Sacituzumab govitecan, FDA tomonidan uroteliy saratonining ilg'or bosqichidan tezda ruxsat oladi
2021 yil avgust: Sacituzumab govitecan (Trodelvy, Immunomedics Inc.) oziq -ovqat va farmatsevtika idorasi tomonidan ilgari qabul qilingan mahalliy rivojlangan yoki metastatik uroteliy saratoni (MUC) bo'lgan bemorlar uchun tez tasdiqlandi.